SANA Sana Biotechnology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1770121 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY36.3%
TTM EPS YoY45.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-79.5%
ROA-36.8%
ROIC (approx.)-109.1%
Asset turnover—
Leverage & solvency
Liabilities / assets52.0%
Debt / equity0.00x
Current ratio1.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $33.93M | $30.73M | $28.72M | $34.92M | $30.11M | $29.76M | $37.19M | $47.04M |
| SG&A expense | $10.94M | $10.78M | $11.46M | $12.19M | $10.29M | $10.34M | $11.48M | $17.28M |
| Operating income | $18.51M | -$65.42M | -$48.61M | -$61.20M | -$43.52M | -$94.97M | -$50.63M | -$50.87M |
| Net income | $20.40M | -$63.63M | -$47.21M | -$58.83M | -$42.15M | -$93.80M | -$49.39M | -$49.07M |
| EBITDA | $21.51M | -$63.22M | -$46.22M | -$58.10M | -$40.31M | -$92.08M | -$46.98M | -$45.16M |
| EPS (basic) | 0.07 | -0.22 | -0.17 | — | -0.16 | -0.39 | -0.21 | — |
| EPS (diluted) | 0.07 | -0.22 | -0.17 | — | -0.16 | -0.39 | -0.21 | — |
| Weighted avg. shares (diluted) | 308.79M | 295.67M | 276.86M | — | 260.49M | 238.41M | 237.58M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.10M | $57.07M | $83.80M | $71.87M | $107.55M | $75.47M | $100.33M | $131.40M |
| Short-term investments | $80.62M | $103.42M | $17.34M | $66.51M | $49.70M | $1.40M | $8.57M | $24.93M |
| Current assets | $132.31M | $170.63M | $111.69M | $148.68M | $161.76M | $82.50M | $112.73M | $160.81M |
| PP&E, net | $23.11M | $25.16M | $25.67M | $26.91M | $29.93M | $33.08M | $73.69M | $77.31M |
| Goodwill | $140.63M | $140.63M | $140.63M | $140.63M | $140.63M | $140.63M | $140.63M | $140.63M |
| Intangibles | $59.20M | $59.20M | $59.20M | $59.20M | $59.20M | $59.20M | $59.20M | $59.20M |
| Total assets | $376.13M | $431.52M | $373.59M | $416.89M | $435.43M | $361.64M | $445.47M | $501.02M |
| Current liabilities | $74.88M | $123.75M | $86.27M | $78.73M | $35.51M | $33.44M | $33.16M | $45.43M |
| Total liabilities | $195.76M | $276.95M | $254.35M | $256.01M | $240.12M | $239.09M | $236.39M | $250.52M |
| Shareholders' equity | $180.36M | $154.57M | $119.24M | $160.88M | $195.31M | $122.56M | $209.08M | $250.50M |
| Shares outstanding | 299.52M | 299.31M | 269.82M | 266.73M | 262.26M | 230.51M | 225.46M | 223.92M |
| Cash flow statement | ||||||||
| Operating cash flow | -$38.75M | -$32.79M | -$37.38M | -$32.64M | -$29.43M | -$33.10M | -$48.66M | -$47.16M |
| Capital expenditure | $791,000 | $1.62M | $288,000 | $873,000 | $41,000 | -$112,000 | $136,000 | $436,000 |
| Free cash flow | -$39.54M | -$34.41M | -$37.67M | -$33.51M | -$29.47M | -$32.99M | -$48.79M | -$47.60M |
| Investing cash flow | $22.35M | -$87.52M | $49.44M | -$16.50M | -$48.02M | $7.68M | $16.60M | $47.09M |
| Financing cash flow | $0 | $93.58M | -$128,000 | $17.65M | $109.54M | $561,000 | $982,000 | $643,000 |
| Depreciation & amortization | $3.00M | $2.20M | $2.39M | $3.10M | $3.20M | $2.90M | $3.65M | $5.70M |
| Stock-based compensation | $5.33M | $5.34M | $5.66M | $6.34M | $5.48M | $6.63M | $7.02M | $6.44M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.